Skip to content
Screener

Beam Therapeutics BEAM Retained Earnings

Retained Earnings at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$14.59B+42.3%
Arrowhead Research logo
Arrowhead ResearchARWR
-$1.73B-21.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$4.81B-13.9%
MGN
MagniteMGNI
-$492.78M+25.3%
Wave Life Sciences logo
Wave Life SciencesWVE
-$1.42B-16.6%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$2.79B-16.7%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$2.81B+52.0%
Enterprise value$2.78B+61.1%
P/S17.2×-13.6×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210338
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 102,741,848 and 101,748,962 issued and outstanding at March 31, 2026 and December 31, 2025, respectively1,0271,017
Additional paid-in capital2,900,0182,877,449
Accumulated other comprehensive (loss) income(1,070)1,111
Accumulated deficit(1,735,537)(1,641,219)
Total stockholders’ equity1,164,4381,238,358
Total liabilities and stockholders’ equity$1,480,798$1,481,177

Item 1. Financial Statements (Unaudited)

FAQ

What is Beam Therapeutics's retained earnings?
Beam Therapeutics (BEAM) reported retained earnings of -$1.74B in Q1 2026.
How has Beam Therapeutics's retained earnings changed year-over-year?
Beam Therapeutics's retained earnings decreased by 3.6% year-over-year, from -$1.68B to -$1.74B.
What is the long-term trend for Beam Therapeutics's retained earnings?
Over 5 years (2020 to 2025), Beam Therapeutics's retained earnings has grown at a 32.8% compound annual growth rate (CAGR), from -$397.64M to -$1.64B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Beam Therapeutics's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude